

with Waldenström's macroglobulinemia: a safety evaluation. *Expert Opin Drug Saf.* 2021;20(9):987-995. doi: 10.1080/14740338.2021.1945031.

155. Castillo JJ, Sarosiek SR, Gustine JN, et al. Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. *Blood Adv.* 2022;6(3):1015-1024. doi: 10.1182/bloodadvances.2021006106.

156. Gustine JN, Sarosiek S, Flynn CA, et al. Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. *Haematologica.* 2022;107(5):1163-1171. doi: 10.3324/haematol.2021.279112.

157. Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. *Blood Rev.* 2020;41:100648. doi: 10.1016/j.blre.2019.100648.

158. Castillo JJ, Joshua Gustine J, 2, Kirsten Meid K, et al. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. *Am J Hematol.* 2016;91(10):1032-1035. doi: 10.1002/ajh.24477.

159. Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. *Lancet Haematol.* 2020;7(11):e827-e837. doi: 10.1016/S2352-3026(20)30224-6.

160. Buske C, Sadullah S, Kastritis E, et al for European Consortium for Waldenström's Macroglobulinemia. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. *Lancet Haematol.* 2018;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5.

161. Castillo JJ, LaMacchia J, Flynn CA, et al. Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib. *Br J Haematol.* 2021;195(3):466-468. doi: 10.1111/bjh.17759.